CLINICAL TRIALS PROFILE FOR SELENOMETHIONINE SE-75

All Clinical Trials for Selenomethionine Se-75

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00112892 ↗	Irinotecan and Selenium in Treating Patients With Advanced Solid Tumors	Completed	Roswell Park Cancer Institute	Phase 1	2004-08-01	RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Selenium may allow higher doses of irinotecan to be given. Giving irinotecan together with selenium may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of selenium when given together with irinotecan in treating patients with advanced solid tumors.
NCT00212186 ↗	Selenium Supplementation of Patients With Cirrhosis	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	N/A	1998-10-01	The purpose of this study is to determine whether patients with liver disease can improve their nutritional selenium status by taking supplemental selenium.
NCT00212186 ↗	Selenium Supplementation of Patients With Cirrhosis	Completed	Vanderbilt University	N/A	1998-10-01	The purpose of this study is to determine whether patients with liver disease can improve their nutritional selenium status by taking supplemental selenium.
NCT00212186 ↗	Selenium Supplementation of Patients With Cirrhosis	Completed	Vanderbilt University Medical Center	N/A	1998-10-01	The purpose of this study is to determine whether patients with liver disease can improve their nutritional selenium status by taking supplemental selenium.
NCT00217516 ↗	Selenium in Treating Patients Who Are Undergoing Brachytherapy for Stage I or Stage II Prostate Cancer	Completed	National Cancer Institute (NCI)	Phase 1	2005-03-01	RATIONALE: The use of nutritional supplements, such as selenium, may stop prostate cancer from growing. Internal radiation, such as brachytherapy, uses radioactive material placed directly into or near a tumor to kill tumor cells. Giving selenium before brachytherapy may be an effective treatment for prostate cancer. PURPOSE: This randomized phase I trial is studying selenium to see how well it works compared to placebo in treating patients who are undergoing brachytherapy for stage I or stage II prostate cancer.
NCT00217516 ↗	Selenium in Treating Patients Who Are Undergoing Brachytherapy for Stage I or Stage II Prostate Cancer	Completed	Roswell Park Cancer Institute	Phase 1	2005-03-01	RATIONALE: The use of nutritional supplements, such as selenium, may stop prostate cancer from growing. Internal radiation, such as brachytherapy, uses radioactive material placed directly into or near a tumor to kill tumor cells. Giving selenium before brachytherapy may be an effective treatment for prostate cancer. PURPOSE: This randomized phase I trial is studying selenium to see how well it works compared to placebo in treating patients who are undergoing brachytherapy for stage I or stage II prostate cancer.
NCT00526890 ↗	Carboplatin, Paclitaxel, Selenomethionine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery	Terminated	Roswell Park Cancer Institute	Phase 2	2006-10-01	RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Selenomethionine may slow the growth of tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together with selenomethionine and radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying the side effects and how well selenomethionine works when given together with carboplatin, paclitaxel, and radiation therapy in treating patients with stage III non-small cell lung cancer that cannot be removed by surgery.

Clinical Trial Conditions for Selenomethionine Se-75

Condition Name

Condition Name for Selenomethionine Se-75
Intervention	Trials
Prostate Cancer	2
Stage III Squamous Cell Carcinoma of the Nasopharynx	1
Liver Cirrhosis	1
Stage III Squamous Cell Carcinoma of the Oropharynx	1

Condition MeSH

Condition MeSH for Selenomethionine Se-75
Intervention	Trials
Prostatic Neoplasms	3
Carcinoma	2
Laryngeal Diseases	1
Paranasal Sinus Neoplasms	1

Clinical Trial Locations for Selenomethionine Se-75

Trials by Country

Trials by Country for Selenomethionine Se-75
Location	Trials
United States	11
New Zealand	3

Trials by US State

Trials by US State for Selenomethionine Se-75
Location	Trials
New York	7
Tennessee	2
Iowa	1
Illinois	1

Clinical Trial Progress for Selenomethionine Se-75

Clinical Trial Phase

Clinical Trial Phase for Selenomethionine Se-75
Clinical Trial Phase	Trials
Phase 2	4
Phase 1/Phase 2	1
Phase 1	4

Clinical Trial Status

Clinical Trial Status for Selenomethionine Se-75
Clinical Trial Phase	Trials
Completed	5
Terminated	3
Recruiting	1

Clinical Trial Sponsors for Selenomethionine Se-75

Sponsor Name

Sponsor Name for Selenomethionine Se-75
Sponsor	Trials
Roswell Park Cancer Institute	6
National Cancer Institute (NCI)	4
Pfizer	1

Sponsor Type

Sponsor Type for Selenomethionine Se-75
Sponsor	Trials
Other	14
NIH	5
Industry	1

Selenomethionine Se-75: Clinical Trials, Market Analysis, and Projections

Overview of Selenomethionine Se-75

Selenomethionine Se-75 is a diagnostic radiopharmaceutical, primarily used in positron-emission tomography (PET) imaging. It was initially developed by Bracco Diagnostics, Inc. and has been utilized in various medical and industrial applications.

Clinical Trials and R&D Status

Current Status

The R&D status of Selenomethionine Se-75 is currently listed as withdrawn, indicating that active development and clinical trials for this compound have been halted[1].

Past Clinical Trials

Historical clinical trials focused on the use of Selenomethionine Se-75 in PET imaging, particularly for brain uptake studies. For example, a study published in the Archives of Neurology investigated the brain uptake of Selenomethionine Se-75 in subjects with phenylketonuria (PKU) and found reduced brain uptake compared to controls, suggesting saturation of the blood-brain barrier carrier system by high blood phenylalanine levels[4].

Market Analysis

Global Market Size and Growth

The global market for Selenium-75, which includes Selenomethionine Se-75, is projected to grow from USD 21.13 million in 2023 to USD 32.88 million by 2030, at a compound annual growth rate (CAGR) of 6.2% during the forecast period. This growth is driven by several factors:

Increasing Medical Demand

Rising cancer incidence rates and the need for early diagnosis and treatment are driving the demand for effective diagnostic tools like Selenium-75, particularly in cancer diagnosis and treatment[2].

Advancements in Medical Imaging Technology

Continuous improvements in imaging technology enhance the application of Selenium-75 in medical imaging, making it a crucial component in the diagnostic arsenal[2].

Expansion of Industrial Applications

The growth in industrial manufacturing and infrastructure construction increases the demand for non-destructive testing, where Selenium-75 is widely used in radiography and thickness measurement[2].

Market Drivers

• Medical Demand: The increasing incidence of cancers and the need for precise diagnostic tools drive the use of Selenium-75 in oncology.
• Technological Advancements: Improvements in imaging technology and the development of new diagnostic devices boost the application of Selenium-75.
• Industrial Growth: Growing infrastructure projects and manufacturing sectors increase the need for non-destructive testing and quality control, where Selenium-75 is essential[2].

Market Restraints

• High Costs: Expensive production processes and handling costs due to the radioactive nature of Selenium-75 are significant restraints.
• Regulatory and Safety Concerns: Strict regulatory requirements and safety risks associated with handling and disposal of radioisotopes are major challenges.
• Limited Availability and Supply Chain Issues: Vulnerability to geopolitical and logistical issues, along with limited production facilities, affect the market supply of Selenium-75[2].

Market Projections

Future Growth Opportunities

• Medical Advancements: Increased demand for precise imaging techniques in oncology, especially for early cancer detection and treatment, will continue to drive the market.
• Technological Innovations: Development of new imaging technologies and portable diagnostic devices will enhance the use of Selenium-75.
• Industrial Expansion: Growing infrastructure projects and manufacturing sectors will increase the need for non-destructive testing and quality control, further boosting the market[2].

Emerging Markets

Industrialization and the improvement of medical infrastructure in emerging markets are expected to drive the demand for Selenium-75. Enhanced global supply chains and advances in logistics technology will make the market supply more stable and efficient[2].

Regulatory and Policy Support

The formulation and implementation of medical and industrial standards by governments and international organizations will promote the widespread application of Selenium-75. Strict management and safety measures for radioisotopes will ensure safe use, increasing market confidence[2].

Therapeutic and Diagnostic Applications

PET Imaging

Selenomethionine Se-75 is used as a PET imaging agent, enhancing the visualization of tumors, particularly in breast cancer diagnosis. Its ability to trace tumors makes it a valuable tool in oncology[1][2].

Antioxidant Properties

Research has shown that selenomethionine can enhance the antioxidant capacity of cells, such as retinal pigment epithelial (RPE) cells, by inducing the cystine/glutamate transporter and increasing glutathione levels[3].

Cardiac Hypertrophy

Studies have indicated that selenomethionine, when co-administered with harmine, can attenuate pathological cardiac hypertrophy by inhibiting glycolytic metabolism, suggesting potential therapeutic applications in cardiovascular diseases[1].

Key Takeaways

• Clinical Trials: While active clinical trials for Selenomethionine Se-75 have been withdrawn, historical trials provided valuable insights into its diagnostic capabilities.
• Market Growth: The global market for Selenium-75 is projected to grow at a CAGR of 6.2% from 2023 to 2030, driven by medical demand, technological advancements, and industrial growth.
• Market Drivers: Increasing medical demand, technological innovations, and industrial expansion are key drivers of the market.
• Restraints: High costs, regulatory and safety concerns, and limited availability are significant restraints.
• Future Opportunities: Medical advancements, technological innovations, and industrial expansion in emerging markets offer future growth opportunities.

FAQs

What is the current R&D status of Selenomethionine Se-75?

The R&D status of Selenomethionine Se-75 is currently listed as withdrawn, indicating that active development and clinical trials have been halted[1].

What are the primary applications of Selenomethionine Se-75?

Selenomethionine Se-75 is primarily used in PET imaging, particularly for tumor tracing, and has antioxidant properties and potential therapeutic applications in cardiovascular diseases[1][2][3].

What drives the growth of the Selenium-75 market?

The growth of the Selenium-75 market is driven by increasing medical demand, advancements in medical imaging technology, expansion of industrial applications, and technological innovations[2].

What are the major restraints to the Selenium-75 market?

Major restraints include high production and handling costs, regulatory and safety concerns, limited availability, and competition from alternative technologies[2].

What are the future growth opportunities for Selenium-75?

Future growth opportunities include medical advancements, technological innovations, industrial expansion in emerging markets, and the development of new applications in various fields[2].

Sources

1. Synapse Patsnap: Selenomethionine Se-75 - Drug Targets, Indications, Patents.
2. QYResearch: Selenium-75 - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030.
3. MDPI: Selenomethionine (Se-Met) Induces the Cystine/Glutamate Transporter in RPE Cells.
4. JAMA Network: Reduced Brain Uptake of Selenomethionine Se 75 in Phenylketonuria.